U.S. Markets open in 2 hrs 51 mins
  • S&P Futures

    3,934.25
    -10.75 (-0.27%)
     
  • Dow Futures

    33,579.00
    -54.00 (-0.16%)
     
  • Nasdaq Futures

    11,520.50
    -45.50 (-0.39%)
     
  • Russell 2000 Futures

    1,810.60
    -3.50 (-0.19%)
     
  • Crude Oil

    74.22
    -0.03 (-0.04%)
     
  • Gold

    1,786.10
    +3.70 (+0.21%)
     
  • Silver

    22.62
    +0.29 (+1.28%)
     
  • EUR/USD

    1.0505
    +0.0036 (+0.3467%)
     
  • 10-Yr Bond

    3.5130
    0.0000 (0.00%)
     
  • Vix

    22.53
    +1.78 (+8.58%)
     
  • GBP/USD

    1.2169
    +0.0035 (+0.2908%)
     
  • USD/JPY

    137.5400
    +0.5800 (+0.4235%)
     
  • BTC-USD

    16,825.33
    -168.31 (-0.99%)
     
  • CMC Crypto 200

    394.89
    -6.92 (-1.72%)
     
  • FTSE 100

    7,507.54
    -13.85 (-0.18%)
     
  • Nikkei 225

    27,686.40
    -199.47 (-0.72%)
     

Regeneron Pharmaceuticals' (NASDAQ:REGN) three-year earnings growth trails the 37% YoY shareholder returns

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But in contrast you can make much more than 100% if the company does well. For instance the Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) share price is 159% higher than it was three years ago. How nice for those who held the stock! It's also up 27% in about a month.

Since the stock has added US$4.8b to its market cap in the past week alone, let's see if underlying performance has been driving long-term returns.

See our latest analysis for Regeneron Pharmaceuticals

There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

During three years of share price growth, Regeneron Pharmaceuticals achieved compound earnings per share growth of 41% per year. We note that the 37% yearly (average) share price gain isn't too far from the EPS growth rate. Coincidence? Probably not. This observation indicates that the market's attitude to the business hasn't changed all that much. Quite to the contrary, the share price has arguably reflected the EPS growth.

You can see how EPS has changed over time in the image below (click on the chart to see the exact values).

earnings-per-share-growth
earnings-per-share-growth

We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here..

A Different Perspective

It's nice to see that Regeneron Pharmaceuticals shareholders have received a total shareholder return of 34% over the last year. Since the one-year TSR is better than the five-year TSR (the latter coming in at 10% per year), it would seem that the stock's performance has improved in recent times. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 2 warning signs for Regeneron Pharmaceuticals you should know about.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here